Key result
Diabetic patients with the BDNF Val/Met genotype who consumed higher dietary total antioxidant capacity (ORAC) had significantly higher triglycerides (β 45.52) compared to those with lower intake.
Why the study?
BDNF has recently been associated with CVD, prompting investigation into whether BDNF Val66Met polymorphisms alter CVD risk markers and interact with dietary total antioxidant capacity to modify these clinical parameters.
Does dietary total antioxidant capacity interact with BDNF Val66Met polymorphism to affect lipid profiles and atherogenic indices in diabetic patients?
Cross-Sectional (n=667)
No
Does dietary total antioxidant capacity interact with BDNF Val66Met polymorphism to affect lipid profiles and atherogenic indices in diabetic patients?
Effect estimate: β 45.52 (95% CI 9.30 to 81.73)
p-value: p=0.01
High dietary total antioxidant capacity does not mitigate the negative lipid profile consequences of the BDNF Val/Met genotype in diabetic patients, whereas it may be protective in Val/Val and Met/Met genotypes.
Should not yet guide dietary advice in diabetic patients; leaves open BDNF genotype-antioxidant interactions on lipids.
Brain-derived neurotrophic factor (BDNF) belongs to the "neurotrophin" family of growth factors, and it has recently been associated to cardiovascular disease (CVD). We anticipated that BDNF Val66Met polymorphisms may alter CVD risk markers such as serum lipid profile differences, and interaction with total antioxidant capacity of diet (DTAC) could alter these clinical parameters. This cross-sectional study consisted of 667 diabetic patients (39.7% male and 60.3% female). DTAC was calculated by international databases. Biochemical markers including total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglyceride (TG), superoxide dismutase (SOD), C-reactive protein (CRP), total antioxidant capacity (TAC), pentraxin-3 (PTX3), isoprostaneF2α (PGF2α). interleukin 18 (IL18), leptin and ghrelin were measured by standard protocol. Atherogenic indices (AIP, AC, CR-I, CR-II) were calculated. Genotyping of the BDNF Val66Met polymorphisms was conducted by the real-time PCR-RFLP method. The gene-diet interactions were evaluated using a generalized linear mode (GLMs). Carriers of the Val/Met genotype who were in the higher median intake of FRAP had lower HDL (P:0.04) and higher TG (P:0.005), AIP (P:0.02) and AC (P:0.02) index compared to Val/Val genotypes with lower median intake. Moreover, diabetic patients with Val/Met genotype who consumed higher ORAC intake had increased odds for anthropometric indices (BMI (P:0.01) and WC (P:0.03)), lipid profiles (TG) (P:0.01), and atherogenic index (AIP) (P:0.02), also decreased odds for HDL (P:0.03) concentration compared to reference group whit lower ORAC intake. Individuals with Val/Met genotype who consumed higher TRAP intake had increased odds for WC (P:0.04), TC (P:0.001), TG (P < 0.001), AIP (P < 0.001) and AC (P < 0.001). Finally, Val/Met patients with a higher median intake of TEAC had higher TG (P:0.02), AIP (P:0.009) and AC (P:0.03) compared to the reference group whit lower TEAC intake. Our study showed that Val/Met genotype had also the highest lipid profile and atherogenic indices even in the highest adherence to DTAC. While it seems that the presence of the Val/Val wild-type and BDNF Met/Met homozygotes in diabetic patients with a high DTAC is a protective factor.
No takes yet. Share an insight, caveat, or question.
Abaj et al. (2021) conducted a cross-sectional in Type 2 Diabetes Mellitus (n=667). High dietary total antioxidant capacity (DTAC) in BDNF Val/Met carriers vs. Val/Val genotype with lower DTAC intake was evaluated on Triglyceride concentration (interaction of Val/Met genotype and high ORAC intake) (β 45.52, 95% CI 9.30 to 81.73, p=0.01). Diabetic patients with the BDNF Val/Met genotype who consumed higher dietary total antioxidant capacity (ORAC) had significantly higher triglycerides (β 45.52) compared to those with lower intake.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: